Clearside Biomedical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Clearside Biomedical kazanç ve gelirinin sırasıyla yıllık 5.1% ve 64.9% oranında artması tahmin edilirken, EPS'nin yıllık 26.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

5.1%

Kazanç büyüme oranı

26.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	21.2%
Gelir büyüme oranı	64.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BST:CLM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	11	-57	-54	N/A	5
12/31/2025	3	-46	-38	N/A	7
12/31/2024	2	-36	-8	N/A	6
9/30/2024	8	-32	-20	-19	N/A
6/30/2024	8	-33	-20	-19	N/A
3/31/2024	8	-35	-20	-19	N/A
12/31/2023	8	-32	-20	-18	N/A
9/30/2023	2	-37	-26	-24	N/A
6/30/2023	2	-36	-26	-24	N/A
3/31/2023	1	-35	-25	-24	N/A
12/31/2022	1	-33	-14	-13	N/A
9/30/2022	27	-5	-3	-3	N/A
6/30/2022	29	-2	0	0	N/A
3/31/2022	30	0	-1	-1	N/A
12/31/2021	30	0	-11	-11	N/A
9/30/2021	4	-25	-20	-20	N/A
6/30/2021	4	-23	-20	-20	N/A
3/31/2021	4	-23	-16	-16	N/A
12/31/2020	8	-18	-13	-13	N/A
9/30/2020	10	-14	-7	-7	N/A
6/30/2020	7	-18	-10	-10	N/A
3/31/2020	6	-18	-17	-17	N/A
12/31/2019	2	-31	-27	-27	N/A
9/30/2019	0	-49	-53	-53	N/A
6/30/2019	0	-67	-67	-67	N/A
3/31/2019	0	-82	-76	-76	N/A
12/31/2018	0	-83	-79	-79	N/A
9/30/2018	0	-78	-70	-70	N/A
6/30/2018	0	-72	N/A	-64	N/A
3/31/2018	0	-65	N/A	-56	N/A
12/31/2017	0	-59	N/A	-51	N/A
9/30/2017	0	-52	N/A	-42	N/A
6/30/2017	0	-39	N/A	-35	N/A
3/31/2017	0	-31	N/A	-29	N/A
12/31/2016	1	-26	N/A	-23	N/A
9/30/2016	1	-21	N/A	-20	N/A
6/30/2016	1	-19	N/A	-17	N/A
3/31/2016	1	-19	N/A	-15	N/A
12/31/2015	N/A	-18	N/A	-14	N/A
9/30/2015	N/A	-15	N/A	-13	N/A
6/30/2015	N/A	-15	N/A	-13	N/A
3/31/2015	N/A	-12	N/A	-11	N/A
12/31/2014	N/A	-10	N/A	-9	N/A
9/30/2014	N/A	-9	N/A	-8	N/A
6/30/2014	N/A	-8	N/A	-7	N/A
3/31/2014	N/A	-8	N/A	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CLM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CLM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CLM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CLM şirketinin gelirinin (yıllık 64.9% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CLM şirketinin gelirinin (yıllık 64.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CLM 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Clearside Biomedical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought €122k worth of stock

New minor risk - Market cap size

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 3Q 2022)

New major risk - Negative shareholders equity

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 1Q 2022)

High number of new directors

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

High number of new directors

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 1Q 2021)

High number of new directors

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

High number of new directors

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

High number of new and inexperienced directors

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.065 loss in 1Q 2020)

Clearside Biomedical, Inc. Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

Full year 2020 earnings released: US$0.39 loss per share (vs US$0.81 loss in FY 2019)

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (Axitinib Injectable Suspension) for the Treatment of Wet AMD

Clearside Biomedical, Inc. to Report Q4, 2020 Results on Mar 10, 2021

New 90-day high: €3.41

Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped from Russell 2000 Dynamic Index

New 90-day high: €3.35

Clearside Biomedical, Inc. Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

New 90-day high: €2.47

Insider recently bought €82k worth of stock

Insider recently bought €87k worth of stock

Insider recently bought €86k worth of stock

New 90-day high: €1.54

Insider recently bought €89k worth of stock

Clearside Biomedical, Inc. Announces Data Presentations at the American Academy Ophthalmology 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology

Third quarter 2020 earnings released: US$0.052 loss per share

Revenue beats expectations